In NPM1-mutated AML, the persistence of DTA (DNMT3A, TET2, and ASXL1) mutations have not been shown to correlate with age, the intensity of induction therapy, or relapse-free survival, and are therefore understood as likely distinct from MRD markers [15,44]. Here, NPM1 is linked to acute myeloid leukemia.